Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 15, Issue 3, 2016, Pages 249-258

  Henderson, Emily J ^a   Lord, Stephen R ^d   Brodie, Matthew A ^d   Gaunt, Daisy M ^b   Lawrence, Andrew D ^c   Close, Jacqueline C T ^d,e   Whone, A L ^b,f   Ben Shlomo, Y ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; LEVODOPA; RIVASTIGMINE;

ACCELEROMETER; ADULT; AGED; ARTICLE; BACKACHE; CARDIOTOXICITY; COGNITION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DYSPEPSIA; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GAIT; HUMAN; HYPERSALIVATION; IMMUNOPATHOLOGY; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MONTREAL COGNITIVE ASSESSMENT; NAUSEA; NUTRITIONAL DISORDER; PARKINSON DISEASE; PARKINSONISM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SKIN DISEASE; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; WALKING; CLINICAL TRIAL; COMPLICATION; FALLING; GAIT DISORDERS, NEUROLOGIC; MIDDLE AGED; OUTCOME ASSESSMENT; VERY ELDERLY;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; RIVASTIGMINE;

EID: 84970016113     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00389-0     Document Type: Article

References (50)

1. 1 Allen, NE, Schwarzel, AK, Canning, CG, Recurrent falls in Parkinson's disease: a systematic review. Park Dis, 2013, 2013, 906274.
2. 2 Wenning, GK, Ebersbach, G, Verny, M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 14 (1999), 947–950.
3. 3 Pickering, RM, Grimbergen, YAM, Rigney, U, et al. A meta-analysis of six prospective studies of falling in Parkinson's disease. Mov Disord 22 (2007), 1892–1900.
4. 4 Wielinski, CL, Erickson-Davis, C, Wichmann, R, Walde-Douglas, M, Parashos, SA, Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes. Mov Disord 20 (2005), 410–415.
5. 5 Mak, MKY, Pang, MYC, Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1-year prospective study. J Neurol 256 (2009), 1689–1695.
6. 6 Low, V, Ben-Shlomo, Y, Coward, E, Fletcher, S, Walker, R, Clarke, CE, Measuring the burden and mortality of hospitalisation in Parkinson's disease: a cross-sectional analysis of the English Hospital Episodes Statistics database 2009–2013. Parkinsonism Relat Disord 21 (2015), 449–454.
7. 7 Schrag, A, Hovris, A, Morley, D, Quinn, N, Jahanshahi, M, Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Park Relat Disord 12 (2006), 35–41.
8. 8 Schenkman, M, Cutson, TMT, Zhu, CW, Whetten-Goldstein, K, A longitudinal evaluation of patients' perceptions of Parkinson's Disease. Gerontologist 42 (2002), 790–798.
9. 9 Morris, ME, Iansek, R, Matyas, TA, Summers, JJ, The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 117 (1994), 1169–1181.
10. 10 Blin, O, Ferrandez, AM, Serratrice, G, Quantitative analysis of gait in Parkinson patients: increased variability of stride length. J Neurol Sci 98 (1990), 91–97.
11. 11 Hausdorff, JM, Cudkowicz, ME, Firtion, R, Wei, JY, Goldberger, AL, Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 13 (1998), 428–437.
12. 12 Nakamura, T, Meguro, K, Sasaki, H, Relationship between falls and stride length variability in senile dementia of the Alzheimer type. Gerontology 42 (1996), 108–113.
13. 13 Feltner, ME, MacRae, PG, McNitt-Gray, JL, Quantitative gait assessment as a predictor of prospective and retrospective falls in community-dwelling older women. Arch Phys Med Rehabil 75 (1994), 447–453.
14. 14 Rochester, L, Hetherington, V, Jones, D, et al. Attending to the task: Interference effects of functional tasks on walking in Parkinson's disease and the roles of cognition, depression, fatigue, and balance. Arch Phys Med Rehabil 85 (2004), 1578–1585.
15. 15 Schaafsma, JD, Giladi, N, Balash, Y, Bartels, AL, Gurevich, T, Hausdorff, JM, Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. J Neurol Sci 212 (2003), 47–53.
16. 16 Dubois, B, Bernard, P, Cognitive deficits in Parkinson's disease. J Neurol 244 (1997), 2–8.
17. 17 Bloem, BR, Grimbergen, YAM, van Dijk, JG, Munneke, M, The ‘posture second’ strategy: a review of wrong priorities in Parkinson's disease. J Neurol Sci 248 (2006), 196–204.
18. 18 Mirelman, A, Herman, T, Brozgol, M, et al. Executive function and falls in older adults: new findings from a five-year prospective study link fall risk to cognition. PLoS One, 7, 2012, e40297.
19. 19 Lord, S, Rochester, L, Hetherington, V, Allcock, LM, Burn, D, Executive dysfunction and attention contribute to gait interference in ‘off’ state Parkinson's Disease. Gait Posture 31 (2010), 169–174.
20. 20 Bond, JM, Morris, M, Goal-directed secondary motor tasks: Their effects on gait in subjects with Parkinson disease. Arch Phys Med Rehabil 81 (2000), 110–116.
21. 21 Plotnik, M, Dagan, Y, Gurevich, T, Giladi, N, Hausdorff, JM, Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson's disease suffering from motor response fluctuations. Exp Brain Res 208 (2011), 169–179.
22. 22 Blin, O, Ferrandez, AM, Pailhous, J, Serratrice, G, Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J Neurol Sci 103 (1991), 51–54.
23. 23 Bohnen, NI, Frey, KA, Studenski, S, et al. Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study. Mov Disord 29 (2014), 1118–1124.
24. 24 Yarnall, A, Rochester, L, Burn, DJ, The Interplay of Cholinergic Function, Attention, and Falls in Parkinson's Disease. Mov Disord 26 (2011), 2496–2503.
25. 25 Karachi, C, Grabli, D, Bernard, FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 120 (2010), 2745–2754.
26. 26 Bohnen, NI, Müller, MLTM, Koeppe, RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73 (2009), 1670–1676.
27. 27 Sarter, M, Kucinski, A, Modeling Parkinson's disease falls associated with brainstem cholinergic systems decline. Behav Neurosci 129 (2015), 96–104.
28. 28 Ferraye, MU, Debû, B, Fraix, V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 133 (2010), 205–214.
29. 29 Nakano, I, Hirano, A, Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 15 (1984), 415–418.
30. 30 Kucinski, A, Paolone, G, Bradshaw, M, Albin, RL, Sarter, M, Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J Neurosci 33 (2013), 16522–16539.
31. 31 Henderson, EJ, Lord, SR, Close, JCT, Lawrence, AD, Whone, A, Ben-Shlomo, Y, The ReSPonD trial–rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. BMC Neurol, 13, 2013, 188.
32. 32 Dubois, B, Burn, D, Goetz, C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 22 (2007), 2314–2324.
33. 33 Lamb, SE, Jørstad-Stein, EC, Hauer, K, Becker, C, Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J Am Geriatr Soc 53 (2005), 1618–1622.
34. 34 Brodie, MAD, Dean, RT, Beijer, TR, et al. Symmetry matched auditory cues improve gait steadiness in most people with Parkinson's disease but not in healthy older people. J Parkinsons Dis 5 (2015), 105–116.
35. 35 Hausdorff, JM, Rios, DA, Edelberg, HK, Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil 82 (2001), 1050–1056.
36. 36 UK Government. The Clinical Trials Regulations—The Medicines for Human Use (Clinical Trials) Regulations (SI 2004 1031). UK, 2009.
37. 37 Tomlinson, CL, Stowe, R, Patel, S, Rick, C, Gray, R, Clarke, CE, Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25 (2010), 2649–2653.
38. 38 Office of Health Economics. An EQ-5D-5L Value Set for England. https://www.ohe.org/news/ohe-seminar-launches-eq-5d-5l-value-set-england (accessed July 16, 2015).
39. 39 Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2004), 2509–2518.
40. 40 Montero-Odasso, M, Wells, JL, Borrie, MJ, Speechley, M, Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol, 9, 2009, 42.
41. 41 Owings, TM, Grabiner, MD, Measuring step kinematic variability on an instrumented treadmill: how many steps are enough?. J Biomech 36 (2003), 1215–1218.
42. 42 Robertson, MC, Campbell, AJ, Herbison, P, Statistical analysis of efficacy in falls prevention trials. J Gerontol A Biol Sci Med Sci 60 (2005), 530–534.
43. 43 Bang, H, Ni, L, Davis, CE, Assessment of blinding in clinical trials. Control Clin Trials 25 (2004), 143–156.
44. 44 Van der Marck, MA, Klok, MPC, Okun, MS, et al. Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. Parkinsonism Relat Disord 20 (2014), 360–369.
45. 45 Canning, CG, Sherrington, C, Lord, SR, et al. Exercise for falls prevention in Parkinson disease. Neurology 84 (2015), 304–312.
46. 46 Li, F, Harmer, P, Fitzgerald, K, et al. Tai Chi and Postural Stability in Patients with Parkinson's Disease. N Engl J Med 366 (2013), 511–519.
47. 47 Pötter-Nerger, M, Volkmann, J, Deep brain stimulation for gait and postural symptoms in Parkinson's disease. Mov Disord 28 (2013), 1609–1615.
48. 48 Chung, K, Lobb, BM, Nutt, JG, Horak, FB, Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75 (2010), 1263–1269.
49. 49 Sarter, M, Albin, RL, Kucinski, A, Lustig, C, Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol 257 (2014), 120–129.
50. 50 Winblad, B, Cummings, J, Andreasen, N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22 (2007), 456–467.